Statins for acute coronary syndrome.

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Acute coronary syndrome (ACS) poses a high risk of recurrent events and mortality in its early stages.
• The short-term impact of early statin treatment on patient outcomes following ACS remains unclear.
• This review is an update of a previous publication from 2011.

Purpose of the Study:

• To evaluate the benefits and harms of early statin administration in ACS patients.
• To assess the effects on mortality and key cardiovascular events.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Included RCTs compared statins with placebo or usual care initiated within 14 days of ACS onset.
• Searches updated through April 2013 across multiple databases, with no language restrictions.

Main Results:

• Eighteen studies involving 14,303 patients were analyzed; no new studies were identified.
• Early statin therapy did not significantly reduce the combined endpoint of death, non-fatal myocardial infarction, or stroke at one or four months.
• A significant reduction in unstable angina incidence was observed at four months (RR 0.76, 95% CI 0.59 to 0.96).
• Myopathy was rare, primarily associated with high-dose simvastatin.

Conclusions:

• Initiating statin therapy within 14 days of ACS does not reduce death, myocardial infarction, or stroke up to four months.
• Early statin use significantly reduces the incidence of unstable angina at four months post-ACS.
• Moderate quality evidence suggests benefits for unstable angina, but overall major event reduction was not statistically significant.